
VEEM shares jumped nearly 19% after completing a major factory expansion. The advanced engineering company is growing its marine, defence, and gyrostabiliser businesses through new products, defence contracts, AUKUS-related opportunities, and increased manufacturing capacity to support future earnings growth.

DXN's share price surged from 2 cents to 14 cents in 2026 after winning major AI and telecommunications infrastructure contracts. The modular data centre specialist is expanding globally, with investors betting on strong growth from AI, cloud, and digital infrastructure markets.

Alterity Therapeutics (ASX: ATH) is advancing its lead neurodegeneration drug, ATH434, toward Phase 3 trials. Following positive clinical data and a 1-for-50 share consolidation, the stock is holding key technical support around 0.450, awaiting a potential upside breakout.

Hammer Metals, a junior explorer focused on copper, gold and lithium in Queensland and WA, broke above resistance on strong Kalman drilling and a trading halt tied to a potential control deal, though overbought technicals and exploration risk remain.

Ardea Resources (ASX: ARL) is an Australian critical minerals developer whose stock has pulled back sharply from 2026 highs, pressured by a DFS delay at its world-class Kalgoorlie Nickel Project, weak nickel prices, and thin institutional support, while technical indicators suggest the $0.50 level may act as a key support floor.

Acrow (ASX: ACF) is technically rebounding, balancing record revenue and strong industrial-access growth with falling margins and rising debt. Future performance depends on profitably converting its $256 million pipeline and breaking key resistance near $1.00.